|
Wednesday, November 15, 2017
Print Current Session:
 |
|
|
Wednesday
SESSION 24:
MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE – NEW DEVELOPMENTS AND HOT TOPICS RELATING TO STENTS
|
|
| SESSION 24 SCHEDULE | |
| 7:46 AM - 7:51 AM | When Are Stents Required In The Era Of DCBs: Is It Best To Leave No Metal Behind |
|
Presenter(s):Koen Deloose, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 7:52 AM - 7:57 AM | Paradigm For Optimal Treatment Of Various Types Of SFA-Pop Occlusive Disease: Which Treatment For Which Lesion: Role Of Multiple Stents And Zilver PTX DESs (Cook) For Long Lesions |
|
Presenter(s):Gary M. Ansel, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 7:58 AM - 8:03 AM | Overview Of Stents For SFA-Pop Lesions: Which Is Best And When: Value Of Local Adventitial Anesthesia And The Presto Technique To Assure Optimal Supera (Abbott) Stent Delivery |
|
Presenter(s):Andrej Schmidt, MD / Dierk Scheinert, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:04 AM - 8:09 AM | Combination Therapy For The SFA: The Evidence For Stent And DCB Choice In This Exciting New Space |
|
Presenter(s):Ramon L. Varcoe, MBBS, MS, PhD, FRACS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:10 AM - 8:15 AM | Comparison Of BMSs vs. DESs For SFA Lesions: Results Of The BATTLE RCT |
|
Presenter(s):Yann Gouëffic, MD, PhD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:16 AM - 8:21 AM | Update On New Developments With The Zilver PTX DES (Cook) For SFA-Pop Lesions: Its Effectiveness Is Maintained In Longer Lesions; Patients With Poor Run-Off, Diabetes And Chronic Renal Failure; And Asian Patient Groups |
|
Presenter(s):Michael D. Dake, MD / Hiroyoshi Yokoi, MD / Kimihiro Komori, MD, PhD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:22 AM - 8:27 AM | IMPERIAL RCT Study Design Comparing Eluvia DESs (Boston Scientific) vs. Zilver PTX DESs (Cook) For The Treatment Of SFA-Pop Lesions |
|
Presenter(s):William A. Gray, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:28 AM - 8:33 AM | 3-Year Results Of The Eluvia DES (Boston Scientific) Shows Maintained Safety And Efficacy In The MAJESTIC RCT With Fem-Pop Lesions: Advantages Of This DES And Why It Is A Better Option Than DCBs For These Lesions |
|
Presenter(s):Stefan Müller-Hülsbeck, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:34 AM - 8:39 AM | Update On 3-Year Experience With The Absorb Everolimus Drug Eluting Bioresorbable Stent (BRS) From Abbott For BTK Lesions: Promising Results Beyond 2 Years And Future Prospects |
|
Presenter(s):Ramon L. Varcoe, MBBS, MS, PhD, FRACS Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:40 AM - 8:45 AM | Advantages Of The Supera Interwoven Biomimetic Stent(Abbott) For Treating Fem-Pop Lesions With Good 5-Year Primary Patency Even With Long And Calcified Lesions |
|
Presenter(s):Peter C.J. Goverde, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:46 AM - 8:51 AM | Current Needs And Solutions In The Treatment Of Severe CLTI (Rutherford 5 And 6) Due To Occlusive Lesions In The Thigh, Leg And Foot: Value Of The Supera Interwoven Stent (Abbott) And The Absorb Drug Eluting BRS (Abbott) |
|
Presenter(s):Steven Kum, MD Location: Grand Ballroom East, 3rd Floor |
|
| View Slides in PDF | |
| 8:52 AM - 8:57 AM | Panel Discussion |
| END OF SESSION 24 | |
| previous | next |